1. Home
  2. AMGN vs CMCSA Comparison

AMGN vs CMCSA Comparison

Compare AMGN & CMCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AMGN
  • CMCSA
  • Stock Information
  • Founded
  • AMGN 1980
  • CMCSA 1963
  • Country
  • AMGN United States
  • CMCSA United States
  • Employees
  • AMGN N/A
  • CMCSA N/A
  • Industry
  • AMGN Biotechnology: Biological Products (No Diagnostic Substances)
  • CMCSA Cable & Other Pay Television Services
  • Sector
  • AMGN Health Care
  • CMCSA Telecommunications
  • Exchange
  • AMGN Nasdaq
  • CMCSA Nasdaq
  • Market Cap
  • AMGN 141.6B
  • CMCSA 162.9B
  • IPO Year
  • AMGN N/A
  • CMCSA 1972
  • Fundamental
  • Price
  • AMGN $272.11
  • CMCSA $36.58
  • Analyst Decision
  • AMGN Buy
  • CMCSA Buy
  • Analyst Count
  • AMGN 22
  • CMCSA 20
  • Target Price
  • AMGN $324.05
  • CMCSA $47.81
  • AVG Volume (30 Days)
  • AMGN 3.5M
  • CMCSA 22.8M
  • Earning Date
  • AMGN 02-04-2025
  • CMCSA 01-30-2025
  • Dividend Yield
  • AMGN 3.50%
  • CMCSA 3.39%
  • EPS Growth
  • AMGN N/A
  • CMCSA 2.79
  • EPS
  • AMGN 7.83
  • CMCSA 3.70
  • Revenue
  • AMGN $32,534,000,000.00
  • CMCSA $123,070,000,000.00
  • Revenue This Year
  • AMGN $20.07
  • CMCSA $4.59
  • Revenue Next Year
  • AMGN $3.59
  • CMCSA N/A
  • P/E Ratio
  • AMGN $34.74
  • CMCSA $9.88
  • Revenue Growth
  • AMGN 21.25
  • CMCSA 1.82
  • 52 Week Low
  • AMGN $253.30
  • CMCSA $36.15
  • 52 Week High
  • AMGN $346.85
  • CMCSA $47.11
  • Technical
  • Relative Strength Index (RSI)
  • AMGN 54.19
  • CMCSA 33.28
  • Support Level
  • AMGN $267.15
  • CMCSA $36.27
  • Resistance Level
  • AMGN $272.82
  • CMCSA $36.85
  • Average True Range (ATR)
  • AMGN 4.68
  • CMCSA 0.62
  • MACD
  • AMGN 2.37
  • CMCSA 0.06
  • Stochastic Oscillator
  • AMGN 75.60
  • CMCSA 20.48

About AMGN Amgen Inc.

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

About CMCSA Comcast Corporation

Comcast is made up of three parts. The core cable business owns networks capable of providing television, internet access, and phone services to 63 million US homes and businesses, or nearly half of the country. About 50% of the locations in this territory subscribe to at least one Comcast service. Comcast acquired NBCUniversal from General Electric in 2011. NBCU owns several cable networks, including CNBC, MSNBC, and USA, the NBC network, the Peacock streaming platform, several local NBC affiliates, Universal Studios, and several theme parks. Sky, acquired in 2018, is a large television provider in the UK and has invested heavily in proprietary content to build this position. Sky is also a large pay-television provider in Italy and has a presence in Germany and Austria.

Share on Social Networks: